Senior Software Engineer - Bioinformatics at Abata Therapeutics

Toronto, Ontario, Canada

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Life SciencesIndustries

Requirements

Candidates must possess a BSc or MS degree in Computer Science, Software Engineering, or a related discipline, with 5+ years of experience as a software engineer, preferably in an industry setting. Essential qualifications include knowledge of cloud infrastructure (AWS, GCP, or Azure), proficiency with Docker, solid Python programming skills, and strong knowledge of pipeline orchestrator frameworks like Metaflow or Snakemake. Experience working with big data, building scalable software solutions, and familiarity with Linux-based operating systems are also required. Desirable qualifications include exposure to large-scale bioinformatics data quality control and visualization, prior experience in healthcare, life sciences, or other regulated industries, and familiarity with R.

Responsibilities

The Senior Software Engineer will be responsible for executing bioinformatics pipelines in a data production cloud environment, maintaining bioinformatics pipelines and other software systems, and improving the scalability of bioinformatics pipelines. They will also support ML scientists using the RunAI GPU scheduling environment, administer AWS cloud accounts, and perform bespoke software engineering tasks related to experimental data generation and analysis. A key responsibility is to understand business domain problems and user needs by collaborating closely with other company members.

Skills

Python

Docker

Linux

Cloud Infrastructure

Pipeline Orchestration

Big Data

Software Engineering

Bioinformatics

Data Quality Control

Data Visualization

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free